mpact of infusion time on the cost of intravenous immunoglobulin therapy at a tertiary hospital outpatient clinic

Eugenia Serramontmany Morante; Carla Alonso Martinez; Anna Roig Izquierdo; Eva Lozano Ortin; Maria Queralt Gorgas Torner; José Bruno Montoro Ronsano

Ayuda

mpact of infusion time on the cost of intravenous immunoglobulin therapy at a tertiary hospital outpatient clinic

Eugenia Serramontmany Morante ^[1] ; Carla Alonso Martinez ^[1] ; Anna Roig Izquierdo ^[1] ; Eva Lozano Ortin ^[1] ; Maria Queralt Gorgas Torner ; José Bruno Montoro Ronsano
1. [1] Hospital Vall d'Hebron
  
  Hospital Vall d'Hebron
  
  Barcelona, España
Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 21, Nº. 2, 2019, págs. 101-106
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Objective: To determine the economic impact of intravenous immunoglobulin (IVIG) infusion time on resource utilization and costs at an outpatient clinic. Method: We performed an opportunity-cost and cost-minimization analysis of IVIG products available in Spain according to infusion time for two populations: adults with primary immunodeficiency (PID) and adults with autoimmune disease. The products studied were Intratect® 100 g/L, Plangamma® 50 g/L, Flebogam-ma® DIF 100 g/L; Gammagard® 50 g/L; Kiovig® 100 g/L; Octagamocta® 100 g/L; Privigen®100g/L. Results: Based on the consideration that four infusion chairs are available for 12 hours a day, 200 days a year at the outpatient clinic and that the hospital receives €205 from the state for each intravenous treatment administered, regardless of infusion time, the opportunity-cost analysis showed that the hospital could generate an additional income of €189,771.42 for patients with PID or autoimmune disease by using the fastest rather than the slowest IVIG product. The cost-minimization analysis showed that a patient with PID would spend 52.07 or 73.91 hours a year at the outpatient clinic depending on whether the fastest or slowest IVIG product was used. This difference of 21.84 hours was even greater for patients with autoimmune disease (57.8 hours). The corresponding difference in annual productivity loss per patient was estimated at €150.11 for PID and €397.35 for autoimmune disease. Conclusions: Infusion rates should be taken into account when selecting an IVIG product. Products with shorter infusion times have a favorable impact on hospital budgets and could also improve patient quality of life